As of November 8, 2026, 2 holders' latest Schedule 13D or 13G filings report owning 5% or more of Dare Bioscience, Inc. The largest reported stake is L1 Capital Global Opportunities Master Fund, Ltd.'s, at 9.99%. 4 filings are on record since October 6, 2025 (Schedule 13G, August 24, 2026).
Sell to companies like Dare Bioscience, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Lind Global Fund III LP · Sole voting: 1,094,890 · Shared voting: 0 · Sole dispositive: 1,094,890 · Shared dispositive: 0 · SCHEDULE 13G, 2026-08-28
- · Reporting person: L1 Capital Global Opportunities Master Fund, Ltd. · Sole voting: 2,028,885 · Shared voting: 0 · Sole dispositive: 2,028,885 · Shared dispositive: 0 · SCHEDULE 13G, 2026-08-24
- · Holder: Law Custodial Inc. · SCHEDULE 13G/A
- · Holder: Law Custodial Inc. · Percent: 15.9% · SCHEDULE 13G
Dare Bioscience, Inc. has 4 Schedule 13D or 13G filings on record since 2025-10-06. 2 holders' latest filing reports 5% or more of common stock, $0.0001 par value. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| L1 Capital Global Opportunities Master Fund, Ltd. | 9.99% | 2,028,885 | SCHEDULE 13G, 2026-08-24 | 2026-08-17 |
| Lind Global Fund III LP | 5.65% | 1,094,890 | SCHEDULE 13G, 2026-08-28 | 2026-08-17 |
| Law Custodial Inc. | SCHEDULE 13G/A, 2025-12-23 | 2025-12-22 |
Holding shares or following this stake? See who's behind Dare Bioscience, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Dare Bioscience, Inc. and the records around it.
The people at Dare Bioscience, Inc.
- William Rastetter is also named on 6 other Form D filings: Iambic Therapeutics, Inc. (Sep 2026)
Dare Bioscience, Inc. elsewhere on the record
- Company profile and every filing Aug 2026
- Form D filing Aug 2026
- Who owns it
Companies that share a holder
- Lind Global Fund III LP also filed stake reports on 11 other companies: DEFSEC Technologies Inc. (Aug 2026), Enveric Biosciences, Inc. (Aug 2026), Iveda Solutions, Inc. (Aug 2026)
- L1 Capital Global Opportunities Master Fund, Ltd. also filed stake reports on 42 other companies: Youlife Group Inc. (Nov 2026), INLIF Ltd (Oct 2026), DarkIris Inc. (Oct 2026)
Watch Dare Bioscience, Inc.
Get an email when Dare Bioscience, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Dare Bioscience, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Dare Bioscience, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Dare Bioscience, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
8 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| L1 Capital Global Opportunities Master Fund, Ltd. | 2,028,885 | 0 | 2,028,885 | 0 | SCHEDULE 13G, 2026-08-24 |
| Lind Global Fund III LP | 1,094,890 | 0 | 1,094,890 | 0 | SCHEDULE 13G, 2026-08-28 |
| Lind Global Partners III LLC | 1,094,890 | 0 | 1,094,890 | 0 | SCHEDULE 13G, 2026-08-28 |
| Easton Jeff | 1,094,890 | 0 | 1,094,890 | 0 | SCHEDULE 13G, 2026-08-28 |
The latest filing identifies Dare Bioscience, Inc. by CUSIP 23666P200 and gives its principal executive office as 3655 Nobel Drive, Suite 260, San Diego, CA 92122 (SCHEDULE 13G, 2026-08-28).
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-10-06 | Law Custodial Inc. | 15.9% | SCHEDULE 13G |
| 2025-12-23 | Law Custodial Inc. | SCHEDULE 13G/A | |
| 2026-08-24 | L1 Capital Global Opportunities Master Fund, Ltd. | 9.99% | SCHEDULE 13G |
| 2026-08-28 | Lind Global Fund III LP | 5.65% | SCHEDULE 13G |
Questions about who owns Dare Bioscience, Inc.
Who owns Dare Bioscience, Inc.?
On this page, 2 holders' latest ownership filings report 5% or more of Dare Bioscience, Inc.: L1 Capital Global Opportunities Master Fund, Ltd. (9.99%, Schedule 13G, filed 2026-08-24) and Lind Global Fund III LP (5.65%, Schedule 13G, filed 2026-08-28).
Who are the largest shareholders of Dare Bioscience, Inc.?
By the share each holder's latest filing reports, the largest holders of Dare Bioscience, Inc. on this page are L1 Capital Global Opportunities Master Fund, Ltd. (9.99%) and Lind Global Fund III LP (5.65%).
When did L1 Capital Global Opportunities Master Fund, Ltd. buy into Dare Bioscience, Inc.?
The filings give report dates, not purchase dates. The earliest filing from L1 Capital Global Opportunities Master Fund, Ltd. on this page is the Schedule 13G, filed 2026-08-24, reporting 9.99%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 4 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Dare Bioscience, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| August 20, 2026 | Form D, private offering | $12.38M sold | Form D page | Source |
| April 17, 2026 | Leadership change filing (Form 8-K, Item 5.02) | — | Leadership changes | Source |
| December 17, 2024 | SBIR Phase II award, Department of Health and Human Services | $2M | SBIR or STTR award | Source |
| November 22, 2024 | Form D, private offering | — | Form D page | Source |
Dare Bioscience, Inc.: every filing and event
Tools for this story
Each opens in a new tab, filled in for Dare Bioscience, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.